ES2482145T3 - Anticuerpos agonistas contra TSHR - Google Patents

Anticuerpos agonistas contra TSHR Download PDF

Info

Publication number
ES2482145T3
ES2482145T3 ES07732193.3T ES07732193T ES2482145T3 ES 2482145 T3 ES2482145 T3 ES 2482145T3 ES 07732193 T ES07732193 T ES 07732193T ES 2482145 T3 ES2482145 T3 ES 2482145T3
Authority
ES
Spain
Prior art keywords
amino acid
cdr
acid sequence
sequence shown
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07732193.3T
Other languages
English (en)
Inventor
Jasvinder-Paul Singh Banga
Jacqueline Ann Gilbert
Deborah Dunn-Walters
Carolyn Padoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606276A external-priority patent/GB0606276D0/en
Priority claimed from GB0607376A external-priority patent/GB0607376D0/en
Application filed by Kings College London filed Critical Kings College London
Application granted granted Critical
Publication of ES2482145T3 publication Critical patent/ES2482145T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo que se une a y puede antagonizar el TSHR humano, que comprende una región variable de cadena pesada que comprende una primera CDR que tiene la secuencia de aminoácidos mostrada en la figura 8 o 9; una segunda CDR que tiene la secuencia de aminoácidos mostrada en la figura 10, 30 o 31; y una tercera CDR que tiene la secuencia de aminoácidos mostrada en la figura 11; y que comprende una región de cadena ligera que comprende una primera CDR que tiene la secuencia de aminoácidos mostrada en la figura 12 o 32; una segunda CDR que tiene la secuencia de aminoácidos mostrada en la figura 13 o 33; y una tercera CDR que tiene la secuencia de aminoácidos mostrada en la figura 14 o 34.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
E07732193
16-07-2014
(continuación)
Ratón
AMPc (pmol/ml) (1 semana después de la 2ª inmunización) TT4 (µg/ml)
4
1,2 81
5
16,6 134
6
59,2 56
7
1,9 89
8
4,0 213
9
37,3 237
10
2,0 84
11
6,1 101
12
18,1 107
13
1,9 138
14
1,5 148
15
1,4 63
16
1,8 60
Ratones control BALB/c
17
0,6 44
18
0,5 62
19
0,5 60
20
0,8 59
Tabla 2: Secuencias de aminoácidos y de nucleótidos mostradas en las figuras:
Aminoácidos de KSAb1
Aminoácidos de KSAb2 Nucleótidos de KSAb1 Nucleótidos de KSAb2
Cadena pesada CDR1
8, 9 8 44, 45 44
Cadena pesada CDR2
10 30, 31 46 61, 62
Cadena pesada CDR3
11 11 47 47
Cadena ligera CDR1
12 32 48 63
Cadena ligera CDR2
13 33 49 64
Cadena ligera CDR3
14 34 50 65
Cadena pesada Fab
15, 16, 17, 18 35, 36, 37 51, 52, 53, 54 66, 67, 68, 69
Cadena ligera Fab
19 38 55 70
Dominio V de cadena pesada
20, 21, 22, 23 39, 40 56, 57, 58, 59 71, 72
Dominio V de cadena ligera
24 41 60 73
scFv
25, 26, 27, 28 42, 43
Conector scFv
29 29
15
Tabla 3: Secuencias Cadena pesada del mAb9 (KSAb1)
imagen14
imagen15
imagen16
imagen17
imagen18
Cadena ligera (KSAb1) del mAb9 Secuencias ScFv (ligera – conector – pesada)
imagen19
imagen20
GGGGSGGGGSGGGGS – PÉPTIDO CONECTOR
imagen21
imagen22
imagen23
Cadena pesada (KSAb2) del mAb17
imagen24
imagen25
imagen26
imagen27
imagen28
Cadena ligera (KSAb2) del mAb17 Secuencias ScFv (ligera – conector – pesada)
imagen29
imagen30
GGGGSGGGGSGGGGS – PÉPTIDO CONECTOR
imagen31
imagen32
imagen33

Claims (1)

  1. imagen1
ES07732193.3T 2006-03-29 2007-03-29 Anticuerpos agonistas contra TSHR Active ES2482145T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0606276 2006-03-29
GB0606276A GB0606276D0 (en) 2006-03-29 2006-03-29 Antibodies
GB0607376A GB0607376D0 (en) 2006-04-12 2006-04-12 Antibodies
GB0607376 2006-04-12
PCT/GB2007/001139 WO2007110648A1 (en) 2006-03-29 2007-03-29 Agonist antibodies against tshr

Publications (1)

Publication Number Publication Date
ES2482145T3 true ES2482145T3 (es) 2014-08-01

Family

ID=38093407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07732193.3T Active ES2482145T3 (es) 2006-03-29 2007-03-29 Anticuerpos agonistas contra TSHR

Country Status (5)

Country Link
US (1) US8603466B2 (es)
EP (1) EP1999153B1 (es)
JP (1) JP5165672B2 (es)
ES (1) ES2482145T3 (es)
WO (1) WO2007110648A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073992B2 (en) * 2008-12-24 2015-07-07 Rsr Ltd. Human anti TSHR antibodies
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023239226A1 (ko) * 2022-06-10 2023-12-14 메디맵바이오 주식회사 Tigit에 특이적으로 결합하는 항체 및 인터류킨-15를 포함하는 융합 단백질 및 이의 용도
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235514T1 (de) * 1994-12-28 2003-04-15 Univ Kentucky Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
EP1196534A1 (en) * 1999-07-01 2002-04-17 The Procter & Gamble Company Transparent or translucent, liquid or gel type automatic dishwashing detergent product
ES2466377T3 (es) * 2001-08-23 2014-06-10 Rsr Limited Regiones epitópicas de un receptor de tirotropina (TSH), usos de las mismas y anticuerpos para las mismas

Also Published As

Publication number Publication date
EP1999153A1 (en) 2008-12-10
JP2009533021A (ja) 2009-09-17
US20100266493A1 (en) 2010-10-21
JP5165672B2 (ja) 2013-03-21
EP1999153B1 (en) 2014-04-23
US8603466B2 (en) 2013-12-10
WO2007110648A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
ES2482145T3 (es) Anticuerpos agonistas contra TSHR
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
JP2020500538A5 (es)
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
IL257281A (en) Anti-pd-1 antibodies and methods of using them
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20131400A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20121023A1 (es) Anticuerpos e inmunoconjugados
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
AR061115A1 (es) Anticuerpos anti- interleuquina 18 (il-18)
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
RS53685B1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
RS52484B (en) CD40 ANTIBODIES
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
JP2010536384A5 (es)
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
RS54452B1 (en) INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
RS53924B1 (en) NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
RS51373B (sr) Antitela za insulinu sličan faktor rasta i receptor
RS53258B (en) HUMAN ANTIBODIES AGAINST HEPATITIS C (HCV) VIRUS AND USE
RS52345B (en) ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING
PE20131334A1 (es) Anticuerpo igg1 humanizado
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.